Abstract

Bexagliflozin (Brenzavvy – TheracosBio), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the FDA to improve glycemic control in adults with type 2 diabetes. It is the fifth SGLT2 inhibitor to be approved in the US for this indication.

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Glycemic Control In Adults
  • Sodium-glucose Cotransporter 2
  • Control In Adults
  • Sodium-glucose Cotransporter 2 Inhibitor
  • Glycemic Control

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes
  • JAMA
  • Jun 16, 2020
Relevant
Not Relevant
Pulse consumption improves indices of glycemic control in adults with and without type 2 diabetes: a systematic review and meta-analysis of acute and long-term randomized controlled trials
  • European Journal of Nutrition
  • Sep 29, 2021
Relevant
Not Relevant
Effects of soluble fiber supplementation on glycemic control in adults with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials
  • Clinical Nutrition
  • Apr 1, 2021
Relevant
Not Relevant
Effects of soluble fiber supplementation on glycemic control in adults with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
  • Clinical nutrition (Edinburgh, Scotland)
  • Jan 1, 2021
Relevant
Not Relevant
A web-based low carbohydrate diet intervention significantly improves glycaemic control in adults with type 2 diabetes: results of the T2Diet Study randomised controlled trial
  • Nutrition & Diabetes
  • Aug 27, 2023
Relevant
Not Relevant
Association Between a Low Carbohydrate Diet, Quality of Life, and Glycemic Control in Australian Adults Living With Type 1 Diabetes: Protocol for a Mixed Methods Pilot Study
  • JMIR Research Protocols
  • Mar 26, 2021
Relevant
Not Relevant
Effect of lactic acid fermented foods on glycemic control in diabetic adults: a systemic review and meta-analysis of randomized controlled trials
  • Critical Reviews in Food Science and Nutrition
  • Sep 26, 2022
Relevant
Not Relevant
Outcomes of mindfulness-based stress reduction and mindfulness-based cognitive therapy in adults with diabetes: a systematic review
  • Apr 18, 2018
Relevant
Not Relevant
Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes
  • Diabetes Technology & Therapeutics
  • Nov 1, 2018
Relevant
Not Relevant
A complete review of empagliflozin: Most specific and potent SGLT2 inhibitor used for the treatment of type 2 diabetes mellitus
  • Diabetes & Metabolic Syndrome: Clinical Research & Reviews
  • May 1, 2019
Relevant
Not Relevant
Saxagliptin and Dapagliflozin for type 2 Diabetes mellitus: A Review
  • Sep 15, 2018
Relevant
Not Relevant
Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor
  • Clinical Pharmacokinetics
  • Mar 1, 2014
Relevant
Not Relevant
Bioequivalence of Canagliflozin/Metformin Immediate Release Fixed- Dose Combination Tablets Compared with Concomitant Administration of Single Components of Canagliflozin and Metformin in Healthy Fed Participants
  • Journal of Bioequivalence & Bioavailability
  • Jan 1, 2014
Relevant
Not Relevant
Dapagliflozin: A new sodium–glucose cotransporter 2 inhibitor for treatment of type 2 diabetes
  • American Journal of Health-System Pharmacy
  • Mar 1, 2015
Relevant
Not Relevant
The relationship between sleep disturbance and glycaemic control in adults with type 2 diabetes: An integrative review
  • Journal of Clinical Nursing
  • Jul 17, 2017
Relevant
Not Relevant
READ MORE FROM

The Medical letter on drugs and therapeutics

Sulbactam/durlobactam (Xacduro) for Acinetobacter pneumonia.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Shockwave therapy for erectile dysfunction.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
In brief: GI effects of GLP-1 receptor agonists.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Ritlecitinib (Litfulo) for severe alopecia areata.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Addendum.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Etrasimod (Velsipity) for ulcerative colitis.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
COVID-19 update: New Novavax vaccine formulation for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Correction.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Antiviral drugs for influenza for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant